This is in contrast to other immunotherapy options, such as the canine melanoma vaccine and canine osteosarcoma vaccine, which present a single antigen to the patient’s immune system (human tyrosinase and HER2/neu, respectively) [62, 63]. This evidence concerns the gene TYR and melanoma.